Pure red cell aplasia following ABO‐incompatible bone marrow transplantation: response to erythropoietin

O. Paltiel, D. Cournoyer, W. Rybka

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Allogeneic bone marrow transplants with major ABO incompatibility may be associated with delayed erythroid engraftment. A case of a male patient with erythroleukemia (blood group O) who received a bone marrow transplant from an HLA‐identical sibling (blood group AB) is reported. The bone marrow transplantation was followed by normal myeloid and megakaryocytic engraftment, but pure red cell aplasia was present for more than 230 days after bone marrow transplant. Despite documentation of an elevated endogenous erythropoietin level (360 mU/mL; normal value, < 19 mU/mL) during the period of absent erythropoiesis, erythroid engraftment was observed soon after the initiation of human recombinant erythropoietin at a dose of 50 U per kg daily. This experience suggests that high‐dose erythropoietin may stimulate sufficient production of erythroid precursors to overcome circulating inhibitors resulting in the correction of pure red cell aplasia. 1993 AABB

Original languageEnglish (US)
Pages (from-to)418-421
Number of pages4
JournalTransfusion
Volume33
Issue number5
DOIs
StatePublished - May 1993

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Hematology

Fingerprint Dive into the research topics of 'Pure red cell aplasia following ABO‐incompatible bone marrow transplantation: response to erythropoietin'. Together they form a unique fingerprint.

  • Cite this